Multiple sclerosis in childhood and adolescence: clinical features and management.
The presentation of multiple sclerosis (MS) in childhood has traditionally been thought to be rare. However, more paediatric cases are now being reported, as a result of progress in diagnostic techniques with the use of sensitive imaging modalities of the brain and spinal cord. Management from an early age and the availability of new treatment options have changed the outcome of paediatric MS. Drugs currently available for treatment, such as beta-interferons, copolymer-1 and intravenous immunoglobulin G, have been found to reduce relapse rate, disease severity and progression to disability in adults, but have not been investigated in children and adolescents. The overall outcome of MS in children is apparently no worse than in adults and the disease may even be less aggressive in children. In juvenile MS, disease progression does not appear to be related to age of onset, severity of neurological involvement or mono/polysymptomatic involvement at presentation. The potential to treat MS has significantly changed the prognosis. Early diagnosis is important, as early treatment can prevent or delay the development of disability.
Pinhas-Hamiel
O
O
Multiple Sclerosis Centre, Sheba Medical Centre, Tel-Hashomer, Ramat-Gan, Israel.
Sarova-Pinhas
I
I
Achiron
A
A
D000293:Adolescent; D000328:Adult; D017677:Age Distribution; D017668:Age of Onset; D002648:Child; D002675:Child, Preschool; D018450:Disease Progression; D005260:Female; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D009103:Multiple Sclerosis / Q000453:epidemiology* / Q000503:physiopathology / Q000517:prevention & control*; D009460:Neurologic Examination; D011379:Prognosis; D012737:Sex Factors